Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

The use of ketogenic diet in special situations: expanding use in intractable epilepsy and other neurologic disorders

  • Lee, Mun-Hyang (Department of Pediatrics, Samsung Medical Center, Sungkyunkwan University School of Medicine)
  • 투고 : 2012.06.15
  • 심사 : 2012.07.24
  • 발행 : 2012.09.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

The ketogenic diet has been widely used and proved to be effective for intractable epilepsy. Although the mechanisms underlying its antiepileptic effects remain to be proven, there are increasing experimental evidences for its neuroprotective effects along with many researches about expanding use of the diet in other neurologic disorders. The first success was reported in glucose transporter type 1 deficiency syndrome, in which the diet served as an alternative metabolic source. Many neurologic disorders share some of the common pathologic mechanisms such as mitochondrial dysfunction, altered neurotransmitter function and synaptic transmission, or abnormal regulation of reactive oxygen species, and the role of the ketogenic diet has been postulated in these mechanisms. In this article, we introduce an overview about the expanding use and emerging trials of the ketogenic diet in various neurologic disorders excluding intractable epilepsy and provide explanations of the mechanisms in that usage.

키워드

참고문헌

  1. Wheless JW. History of the ketogenic diet. Epilepsia 2008;49 Suppl 8:3-5.
  2. Coppola G, Veggiotti P, Cusmai R, Bertoli S, Cardinali S, Dionisi-Vici C, et al. The ketogenic diet in children, adolescents and young adults with refractory epilepsy: an Italian multicentric experience. Epilepsy Res 2002;48:221-7. https://doi.org/10.1016/S0920-1211(01)00315-1
  3. Than KD, Kossoff EH, Rubenstein JE, Pyzik PL, McGrogan JR, Vining EP. Can you predict an immediate, complete, and sustained response to the ketogenic diet? Epilepsia 2005;46:580-2. https://doi.org/10.1111/j.0013-9580.2005.53304.x
  4. Payne NE, Cross JH, Sander JW, Sisodiya SM. The ketogenic and related diets in adolescents and adults--a review. Epilepsia 2011;52:1941-8. https://doi.org/10.1111/j.1528-1167.2011.03287.x
  5. Nordli DR Jr, Kuroda MM, Carroll J, Koenigsberger DY, Hirsch LJ, Bruner HJ, et al. Experience with the ketogenic diet in infants. Pediatrics 2001;108:129-33. https://doi.org/10.1542/peds.108.1.129
  6. Neal EG, Chaffe H, Schwartz RH, Lawson MS, Edwards N, Fitzsimmons G, et al. The ketogenic diet for the treatment of childhood epilepsy: a randomised controlled trial. Lancet Neurol 2008;7:500-6. https://doi.org/10.1016/S1474-4422(08)70092-9
  7. Hartman AL, Gasior M, Vining EP, Rogawski MA. The neuropharmacology of the ketogenic diet. Pediatr Neurol 2007;36:281-92. https://doi.org/10.1016/j.pediatrneurol.2007.02.008
  8. Bough KJ, Rho JM. Anticonvulsant mechanisms of the ketogenic diet. Epilepsia 2007;48:43-58.
  9. Stafstrom CE, Rho JM. The ketogenic diet as a treatment paradigm for diverse neurological disorders. Front Pharmacol 2012;3:59.
  10. Schwartzkroin PA. Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet. Epilepsy Res 1999;37:171-80. https://doi.org/10.1016/S0920-1211(99)00069-8
  11. Baranano KW, Hartman AL. The ketogenic diet: uses in epilepsy and other neurologic illnesses. Curr Treat Options Neurol 2008;10:410-9. https://doi.org/10.1007/s11940-008-0043-8
  12. Kossoff EH, Zupec-Kania BA, Rho JM. Ketogenic diets: an update for child neurologists. J Child Neurol 2009;24:979-88. https://doi.org/10.1177/0883073809337162
  13. Milder J, Patel M. Modulation of oxidative stress and mitochondrial function by the ketogenic diet. Epilepsy Res 2012;100:295-303. https://doi.org/10.1016/j.eplepsyres.2011.09.021
  14. De Vivo DC, Trifiletti RR, Jacobson RI, Ronen GM, Behmand RA, Harik SI. Defective glucose transport across the blood-brain barrier as a cause of persistent hypoglycorrhachia, seizures, and developmental delay. N Engl J Med 1991;325:703-9. https://doi.org/10.1056/NEJM199109053251006
  15. Wang D, Pascual JM, Yang H, Engelstad K, Jhung S, Sun RP, et al. Glut- 1 deficiency syndrome: clinical, genetic, and therapeutic aspects. Ann Neurol 2005;57:111-8. https://doi.org/10.1002/ana.20331
  16. De Vivo DC, Leary L, Wang D. Glucose transporter 1 deficiency syndrome and other glycolytic defects. J Child Neurol 2002;17 Suppl 3:3S15-23. https://doi.org/10.1177/088307380201700501
  17. Klepper J, Leiendecker B, Bredahl R, Athanassopoulos S, Heinen F, Gertsen E, et al. Introduction of a ketogenic diet in young infants. J Inherit Metab Dis 2002;25:449-60. https://doi.org/10.1023/A:1021238900470
  18. Wheless JW. The ketogenic diet: Fa(c)t or fiction. J Child Neurol 1995;10:419-23. https://doi.org/10.1177/088307389501000601
  19. Klepper J, Scheffer H, Leiendecker B, Gertsen E, Binder S, Leferink M, et al. Seizure control and acceptance of the ketogenic diet in GLUT1 deficiency syndrome: a 2- to 5-year follow-up of 15 children enrolled prospectively. Neuropediatrics 2005;36:302-8. https://doi.org/10.1055/s-2005-872843
  20. Pons R, Collins A, Rotstein M, Engelstad K, De Vivo DC. The spectrum of movement disorders in Glut-1 deficiency. Mov Disord 2010;25:275-81. https://doi.org/10.1002/mds.22808
  21. Veggiotti P, Teutonico F, Alfei E, Nardocci N, Zorzi G, Tagliabue A, et al. Glucose transporter type 1 deficiency: ketogenic diet in three patients with atypical phenotype. Brain Dev 2010;32:404-8. https://doi.org/10.1016/j.braindev.2009.04.013
  22. Roulet-Perez E, Ballhausen D, Bonafe L, Cronel-Ohayon S, Maeder- Ingvar M. Glut-1 deficiency syndrome masquerading as idiopathic generalized epilepsy. Epilepsia 2008;49:1955-8. https://doi.org/10.1111/j.1528-1167.2008.01654.x
  23. Patel KP, O'Brien TW, Subramony SH, Shuster J, Stacpoole PW. The spectrum of pyruvate dehydrogenase complex deficiency: clinical, biochemical and genetic features in 371 patients. Mol Genet Metab 2012;105:34-43. https://doi.org/10.1016/j.ymgme.2011.09.032
  24. Wexler ID, Hemalatha SG, McConnell J, Buist NR, Dahl HH, Berry SA, et al. Outcome of pyruvate dehydrogenase deficiency treated with ketogenic diets. Studies in patients with identical mutations. Neurology 1997;49:1655-61. https://doi.org/10.1212/WNL.49.6.1655
  25. Naito E, Ito M, Yokota I, Saijo T, Chen S, Maehara M, et al. Concomitant administration of sodium dichloroacetate and thiamine in west syndrome caused by thiamine-responsive pyruvate dehydrogenase complex deficiency. J Neurol Sci 1999;171:56-9. https://doi.org/10.1016/S0022-510X(99)00250-6
  26. Bough KJ, Wetherington J, Hassel B, Pare JF, Gawryluk JW, Greene JG, et al. Mitochondrial biogenesis in the anticonvulsant mechanism of the ketogenic diet. Ann Neurol 2006;60:223-35. https://doi.org/10.1002/ana.20899
  27. Kim do Y, Vallejo J, Rho JM. Ketones prevent synaptic dysfunction induced by mitochondrial respiratory complex inhibitors. J Neurochem 2010;114:130-41.
  28. Wallace DC, Fan W, Procaccio V. Mitochondrial energetics and therapeutics. Annu Rev Pathol 2010;5:297-348. https://doi.org/10.1146/annurev.pathol.4.110807.092314
  29. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu Rev Genet 2005;39:359-407. https://doi.org/10.1146/annurev.genet.39.110304.095751
  30. Kang HC, Lee YM, Kim HD, Lee JS, Slama A. Safe and effective use of the ketogenic diet in children with epilepsy and mitochondrial respiratory chain complex defects. Epilepsia 2007;48:82-8.
  31. Kossoff EH, Rho JM. Ketogenic diets: evidence for short- and long-term efficacy. Neurotherapeutics 2009;6:406-14. https://doi.org/10.1016/j.nurt.2009.01.005
  32. Swoboda KJ, Specht L, Jones HR, Shapiro F, DiMauro S, Korson M. Infantile phosphofructokinase deficiency with arthrogryposis: clinical benefit of a ketogenic diet. J Pediatr 1997;131:932-4. https://doi.org/10.1016/S0022-3476(97)70048-9
  33. Busch V, Gempel K, Hack A, Müller K, Vorgerd M, Lochmüller H, et al. Treatment of glycogenosis type V with ketogenic diet. Ann Neurol 2005;58:341.
  34. Nabbout R, Vezzani A, Dulac O, Chiron C. Acute encephalopathy with inflammation-mediated status epilepticus. Lancet Neurol 2011;10:99-108. https://doi.org/10.1016/S1474-4422(10)70214-3
  35. Shorvon S, Ferlisi M. The treatment of super-refractory status epilepticus: a critical review of available therapies and a clinical treatment protocol. Brain 2011;134(Pt 10):2802-18. https://doi.org/10.1093/brain/awr215
  36. Nam SH, Lee BL, Lee CG, Yu HJ, Joo EY, Lee J, et al. The role of ketogenic diet in the treatment of refractory status epilepticus. Epilepsia 2011;52:e181-4. https://doi.org/10.1111/j.1528-1167.2011.03289.x
  37. Nangia S, Caraballo RH, Kang HC, Nordli DR, Scheffer IE. Is the ketogenic diet effective in specific epilepsy syndromes? Epilepsy Res 2012;100:252-7. https://doi.org/10.1016/j.eplepsyres.2012.01.015
  38. Dravet C. The core Dravet syndrome phenotype. Epilepsia 2011;52 Suppl 2:3-9.
  39. Mastrangelo M, Leuzzi V. Genes of early-onset epileptic encephalopathies: from genotype to phenotype. Pediatr Neurol 2012;46:24-31. https://doi.org/10.1016/j.pediatrneurol.2011.11.003
  40. Caraballo RH, Cersósimo RO, Sakr D, Cresta A, Escobal N, Fejerman N. Ketogenic diet in patients with Dravet syndrome. Epilepsia 2005;46:1539-44. https://doi.org/10.1111/j.1528-1167.2005.05705.x
  41. Caraballo R, Vaccarezza M, Cersosimo R, Rios V, Soraru A, Arroyo H, et al. Long-term follow-up of the ketogenic diet for refractory epilepsy: multicenter Argentinean experience in 216 pediatric patients. Seizure 2011;20:640-5. https://doi.org/10.1016/j.seizure.2011.06.009
  42. Kang HC, Kim YJ, Kim DW, Kim HD. Efficacy and safety of the ketogenic diet for intractable childhood epilepsy: Korean multicentric experience. Epilepsia 2005;46:272-9. https://doi.org/10.1111/j.0013-9580.2005.48504.x
  43. Nabbout R, Copioli C, Chipaux M, Chemaly N, Desguerre I, Dulac O, et al. Ketogenic diet also benefits Dravet syndrome patients receiving stiripentol: a prospective pilot study. Epilepsia 2011;52:e54-7. https://doi.org/10.1111/j.1528-1167.2011.03107.x
  44. Doose H, Gerken H, Leonhardt R, Volzke E, Volz C. Centrencephalic myoclonic-astatic petit mal. Clinical and genetic investigation. Neuropadiatrie 1970;2:59-78. https://doi.org/10.1055/s-0028-1091841
  45. Kelley SA, Kossoff EH. Doose syndrome (myoclonic-astatic epilepsy): 40 years of progress. Dev Med Child Neurol 2010;52:988-93. https://doi.org/10.1111/j.1469-8749.2010.03744.x
  46. Oguni H, Tanaka T, Hayashi K, Funatsuka M, Sakauchi M, Shirakawa S, et al. Treatment and long-term prognosis of myoclonic-astatic epilepsy of early childhood. Neuropediatrics 2002;33:122-32. https://doi.org/10.1055/s-2002-33675
  47. Laux LC, Devonshire KA, Kelly KR, Goldstein J, Nordli DR Jr.. Efficacy of the ketogenic diet in myoclonic epilepsy of Doose. Epilepsia 2004;45 (Suppl 7):251.
  48. Holtkamp M, Othman J, Buchheim K, Meierkord H. Predictors and prognosis of refractory status epilepticus treated in a neurological intensive care unit. J Neurol Neurosurg Psychiatry 2005;76:534-9. https://doi.org/10.1136/jnnp.2004.041947
  49. Rossetti AO, Logroscino G, Bromfield EB. Refractory status epilepticus: effect of treatment aggressiveness on prognosis. Arch Neurol 2005; 62:1698-702. https://doi.org/10.1001/archneur.62.11.1698
  50. Nabbout R, Mazzuca M, Hubert P, Peudennier S, Allaire C, Flurin V, et al. Efficacy of ketogenic diet in severe refractory status epilepticus initiating fever induced refractory epileptic encephalopathy in school age children (FIRES). Epilepsia 2010;51:2033-7. https://doi.org/10.1111/j.1528-1167.2010.02703.x
  51. Appleton DB, DeVivo DC. An animal model for the ketogenic diet. Epilepsia 1974;15:211-27. https://doi.org/10.1111/j.1528-1157.1974.tb04943.x
  52. Bough K. Energy metabolism as part of the anticonvulsant mechanism of the ketogenic diet. Epilepsia 2008;49 Suppl 8:91-3. https://doi.org/10.1111/j.1528-1167.2008.01846.x
  53. Kapogiannis D, Mattson MP. Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer's disease. Lancet Neurol 2011;10:187-98. https://doi.org/10.1016/S1474-4422(10)70277-5
  54. Balietti M, Casoli T, Di Stefano G, Giorgetti B, Aicardi G, Fattoretti P. Ketogenic diets: an historical antiepileptic therapy with promising potentialities for the aging brain. Ageing Res Rev 2010;9:273-9. https://doi.org/10.1016/j.arr.2010.02.003
  55. Henderson ST, Vogel JL, Barr LJ, Garvin F, Jones JJ, Costantini LC. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond) 2009;6:31. https://doi.org/10.1186/1743-7075-6-31
  56. Kashiwaya Y, Takeshima T, Mori N, Nakashima K, Clarke K, Veech RL. D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease. Proc Natl Acad Sci U S A 2000;97:5440-4. https://doi.org/10.1073/pnas.97.10.5440
  57. Yao J, Chen S, Mao Z, Cadenas E, Brinton RD. 2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. PLoS One 2011;6:e21788. https://doi.org/10.1371/journal.pone.0021788
  58. Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology 2005;64:728-30. https://doi.org/10.1212/01.WNL.0000152046.11390.45

피인용 문헌

  1. Ketogenic diet in endocrine disorders: Current perspectives vol.63, pp.4, 2012, https://doi.org/10.4103/jpgm.jpgm_16_17
  2. Ketogenic diet in epilepsy: an updated review vol.26, pp.1, 2012, https://doi.org/10.21307/jepil-2018-004
  3. Case Report: The Association of Wilson Disease in a Patient With Ataxia and GLUT-1 Deficiency vol.9, pp.None, 2012, https://doi.org/10.3389/fped.2021.750593
  4. Ketogenic Dietary Therapies in Patients with Autism Spectrum Disorder: Facts or Fads? A Scoping Review and a Proposal for a Shared Protocol vol.13, pp.6, 2012, https://doi.org/10.3390/nu13062057